SensoDetect AB (publ) today announced the successful completion of its presentation at the Redeye Theme: Medtech & Diagnostics event on 12 November 2025. CEO PA Hedin and Dr. Mohamed Hussein Atwa, Head of Clinical Research, presented the company's technological evolution, commercial strategy, and transition toward large-scale, population-level neuro-auditory screening.

The session consisted of a 12-minute presentation followed by an 8-minute investor Q&A, with strong engagement from both institutional and private investors. The full presentation is available on Redeye's platform:

https://www.redeye.se/video/event-presentation/1138517/sensodetect-ceo-pa-hedin-and-head-of-clinical-research-dr-mohamed-atwa-present-at-redeye-theme-event-medtech-diagnostics-november-12-2025

Highlights Presented at the Event

1. A Global Problem: Slow, Subjective and Inconsistent Mental-Health Identification

· Traditional ADHD and autism assessments remain slow, subjective, and highly resource dependent.

· Global demand is rising, with increasing rates of late diagnoses.

· SensoDetect addresses this through fast, objective, scalable screening.

2. The Global Solution - Objective Neuro-Auditory Screening

SensoDetect demonstrated its BERA-based screening workflow:

· 5-15 min auditory test (patented 13-click protocol).

· <10 second statistical and AI-driven analysis.

· Clear Low / Moderate / High risk output.

Based on over 30 years of psychoacoustic and neuroscience research at Lund University.

3. Market Opportunity & Scalable Revenue Model

· ADHD & Autism markets exceed USD 500B globally.

· Business model: device sales + device placement + per-screening revenue + advanced statistical and AI/cloud services.

· Recurring revenues grow as screening volumes scale.

· Statistical and in-line machine learning models improve AI performance strengthens with every new screening - a self-reinforcing competitive moat.

4. Strategic Shift: Screening First

SensoDetect is transitioning from a niche diagnostic tool to a population-scale screening platform.

Primary environments targeted:

· Private and semi-private schools.

· Large corporations (e.g. personnel with stressful and critical functions)

· Sensodetect owned ADHD clinical support centers for screening

· Early childhood and neonatal screening programs

5. Three New Pillars of Growth

1. ADHD Clinical Support Centers - high-volume, mixed-diagnostic hubs (also for large corporations).

2. School-Based Screening - partnerships with private school networks and government authorities.

3. Autism & Neonatal Screening - early identification through integration with newborn screening.

6. ABR as a Universal Neurodevelopmental Biomarker

· Measures neural timing and brainstem connectivity

· Can detect deviations months or years before behavioral symptoms

· Independent of culture, language, or observer bias

7. China & MENA Strategy Updates

China - High-Priority, Policy-Aligned Expansion

Through Beijing Mind Exploration Medical Technology Co., Ltd., SensoDetect advances:

· Large-scale pilots in Beijing & Guangdong

· Education bureau MOUs

· Local cloud/edge processing for data residency

· NMPA-aligned regulatory roadmap

MENA Region - Rapid Policy Momentum

Saudi Arabia:

· Alignment with Vision 2030

· School mass-screening suitability

· Partnerships with major healthcare groups and opening of clinical support centers for screening

UAE:

· 2024 National School Health Screening Guideline includes mental-health screening pathways

· Full coverage 6 years-Grade 12

· Fast approvals and standardized clinical workflows (DHA/MoHAP)

· Ideal for SensoDetect's fast and objective test

8. Global Standardization Roadmap (2025-2028)

· Accuracy approaching ~90%

· Multi-condition screening expansion

· Launch of the Neuro Status Index (NSI)

· Integration into neonatal programs

· Scaling international device placement and per-screening revenues

Quotes

PA Hedin, CEO

"Every parent deserves clarity, not years of uncertainty. When a child struggles, the whole family feels it - and far too many are left waiting for answers that come too late. With SensoDetect, we want to change that. By listening directly to the brain, we can provide fast, objective insights that help children earlier and support parents sooner. Our mission is simple: no family should ever feel lost in the system again. SensoDetect is now well on the way in building the global standard neuro-developmental screening for everyone's benefit."

Dr. Mohamed Hussein Atwa

"With SensoDetect, we move from subjective observation to measurable brain data, redefining mental-health screening for schools, clinics, and communities worldwide."